GSK732461 + chloroquine

GSK732461 + chloroquine is an experimental combination investigated by GSK for the prevention or treatment of HIV/AIDS. The combination consists of GSK732461, a candidate HIV vaccine, and chloroquine (marketed under the brand name Nivaquine), a 4-aminoquinoline derivative primarily known as an antimalarial and immunomodulatory small molecule. The rationale for the combination was to evaluate whether a single dose of chloroquine could modulate or enhance the immune response (such as T-cell or antibody responses) elicited by the HIV vaccine. A Phase 1 clinical trial (NCT00972725) was conducted in healthy volunteers to assess the safety and immunogenicity of this approach. While the specific composition of GSK732461 (e.g., viral vector or protein subunit) has not been widely disclosed in public pipelines, the program represents an early-stage effort to optimize HIV vaccine efficacy through pharmacological immune modulation.

Brand names

Nivaquine

Other names

GSK732461 + NivaquineHIV vaccine 732461 + chloroquine